TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37348272

Group type: EXPERIMENTAL
Intervention: Revascularization rate in patients with severely reduced LVEF
Number of subjects: 1657

Group type: EXPERIMENTAL
Intervention: In-hospital mortality in patients with severely reduced LVEF
Number of subjects: 1657

Group type: EXPERIMENTAL
Intervention: Prescription of optimal cardioprotective therapy at discharge
Number of subjects: 1657
Study: 37348348

Group type: EXPERIMENTAL
Intervention: 2-year icotinib (125 mg thrice daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: 1-year icotinib (125 mg thrice daily)
Number of subjects: 109
Study: 37348519

Group type: EXPERIMENTAL
Intervention: Omicron BA.1 monovalent booster (50 μg)
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: Omicron BA.1 bivalent booster (50 μg)
Number of subjects: 3548

Group type: COMPARATOR
Intervention: mRNA-1273 (50 μg)
Number of subjects: 3548
Study: 37348524

Group type: EXPERIMENTAL
Intervention: Aviptadil
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 473

Group type: COMPARATOR
Intervention: Remdesivir matched placebo
Number of subjects: 473
Study: 37348800

Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Area Pacing (LBBAP)
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: His-Bundle Pacing (HBP)
Number of subjects: 870
Study: 37348816

Group type: EXPERIMENTAL
Intervention: Intravenous ferumoxytol (2 infusions of 510 mg approximately 7 days apart)
Number of subjects: 124
Study: 37348817

Group type: EXPERIMENTAL
Intervention: Intravenous ferumoxytol (2 infusions of 510 mg)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Oral ferrous sulfate (325 mg twice daily)
Number of subjects: 124
Study: 37348996

Group type: EXPERIMENTAL
Intervention: Cemiplimab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 37349083

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 0
Study: 37349100

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (4 mg/kg)
Number of subjects: 85
Study: 37349132

Group type: EXPERIMENTAL
Intervention: Active Device (AD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive Device (ID)
Number of subjects: 0
Study: 37349318

Group type: EXPERIMENTAL
Intervention: Nivolumab plus concurrent chemoradiotherapy (CRT)
Number of subjects: 16
Study: 37349632

Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cerebellar tACS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 26
Study: 37349673

Group type: EXPERIMENTAL
Intervention: Rapid EtG test strips
Number of subjects: 505
Study: 37349694

Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment
Number of subjects: 20
Study: 37349703

Group type: EXPERIMENTAL
Intervention: IntuBrite® (INT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MCL)
Number of subjects: 86
Study: 37349747

Group type: EXPERIMENTAL
Intervention: Dentist-administered cognitive behavioural therapy (D-CBT, n=36)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Four Habits Model combined with midazolam (Four Habits/midazolam, n=41)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dentist-administered cognitive behavioural therapy (D-CBT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Four Habits Model combined with midazolam (Four Habits/midazolam)
Number of subjects: 82
Study: 37349825

Group type: EXPERIMENTAL
Intervention: Digital health education tool (dHET)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard consent (SC)
Number of subjects: 40
Study: 37349828

Group type: EXPERIMENTAL
Intervention: Blended self-management program 'Partner in Balance'
Number of subjects: 100

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 100
Study: 37349841

Group type: EXPERIMENTAL
Intervention: Pregabalin 25 mg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Pregabalin (all doses)
Number of subjects: 132
Study: 37349895

Group type: EXPERIMENTAL
Intervention: FET
Number of subjects: 606

Group type: COMPARATOR
Intervention: fresh-ET
Number of subjects: 606

Group type: COMPARATOR
Intervention: NC
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: FET (girls)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: FET (boys)
Number of subjects: 606

Group type: COMPARATOR
Intervention: fresh-ET (girls)
Number of subjects: 606

Group type: COMPARATOR
Intervention: NC (girls)
Number of subjects: 606

Group type: COMPARATOR
Intervention: NC (boys)
Number of subjects: 606
Study: 37350052

Group type: EXPERIMENTAL
Intervention: Viz RECRUIT SDH (AI-based software)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pre-AI cohort
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Post-AI cohort
Number of subjects: 19
Study: 37350119

Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 0
Study: 37350280

Group type: EXPERIMENTAL
Intervention: Risk model for stroke prediction based on history of previous stroke, insulin-treated diabetes, and plasma N-terminal pro-B-type natriuretic peptide level.
Number of subjects: 5126

Group type: EXPERIMENTAL
Intervention: Third tertile risk score for stroke prediction.
Number of subjects: 5126

Group type: EXPERIMENTAL
Intervention: Second tertile risk score for stroke prediction.
Number of subjects: 5126

Group type: EXPERIMENTAL
Intervention: Patients in the third tertile risk score.
Number of subjects: 5126

Group type: EXPERIMENTAL
Intervention: Risk model discrimination.
Number of subjects: 5126
Study: 37350404

Group type: EXPERIMENTAL
Intervention: S-ICD extraction procedure
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Simple manual traction for lead removal
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hospitalization time for non-infectious indications
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hospitalization time for infectious indications
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Post-extraction intravenous antibiotics
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy duration
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Re-implantation during the same procedure
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Complications over a median follow-up period
Number of subjects: 71
Study: 37350492

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I measurement at presentation, threshold of 2 ng/L
Number of subjects: 41103

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I measurement at presentation, threshold of 5 ng/L
Number of subjects: 41103

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I measurement at presentation, threshold of 99th centile
Number of subjects: 41103

Group type: COMPARATOR
Intervention: External validation cohort
Number of subjects: 41103
Study: 37350574

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) plus best medical treatment (BMT)
Number of subjects: 824

Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 824
Study: 37350585

Group type: EXPERIMENTAL
Intervention: iTind
Number of subjects: 50
Study: 37350968

Group type: EXPERIMENTAL
Intervention: Atezolizumab with EC/EP for two cycles followed by concurrent palliative HFRT and two cycles of atezolizumab with EC/EP, then atezolizumab every 3 weeks for a maximum of 2 years.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Concurrent hypofractionated thoracic radiotherapy (HFRT) with immunochemotherapy.
Number of subjects: 40
Study: 37350989

Group type: EXPERIMENTAL
Intervention: Nangibotide (1.0 mg/kg/h)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 37350990

Group type: EXPERIMENTAL
Intervention: Weight-adjusted intermediate dose of low-molecular-weight heparin
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Fixed-dose of low-molecular-weight heparin
Number of subjects: 1000
Study: 37351068

Group type: EXPERIMENTAL
Intervention: Low tidal volume strategy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Intermediate tidal volume strategy
Number of subjects: 98
Study: 37351105

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention focusing on improving diet, physical activity, and mental health in the mother, and supporting breastfeeding, delaying solid food introduction, reducing sweetened beverage consumption, increasing family physical activity, and improving parental responsiveness.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active guidelines-based usual-care group (Control)
Number of subjects: 0
Study: 37351147

Group type: EXPERIMENTAL
Intervention: Y90 TARE using personalized dosimetry
Number of subjects: 18
Study: 37351372

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy
Number of subjects: 105
Study: 37351408

Group type: EXPERIMENTAL
Intervention: NiTi-TE archwires
Number of subjects: 52

Group type: COMPARATOR
Intervention: NiTi-PSE archwires
Number of subjects: 52
Study: 37351456

Group type: EXPERIMENTAL
Intervention: Adintrevimab (300 mg, single intramuscular injection)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 37351464

Group type: EXPERIMENTAL
Intervention: Telehealth-based training sessions
Number of subjects: 18
Study: 37351564

Group type: EXPERIMENTAL
Intervention: Orforglipron (12, 24, 36, or 45 mg)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 37351585

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (12 weeks acute phase and 16 weeks continuation phase)
Number of subjects: 425
Study: 37351639

Group type: EXPERIMENTAL
Intervention: Knowledge of fatigue guidelines
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Self-efficacy to intervene for fatigue
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: General knowledge about fatigue
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Awareness of empirical evidence for psychotherapeutic interventions
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Everyday physical activity awareness
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Yoga awareness
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions awareness
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Knowledge of resistance/endurance training
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Recommendation frequency for resistance/endurance training
Number of subjects: 144
Study: 37351640

Group type: EXPERIMENTAL
Intervention: Bilateral parallel elliptical flap (BPEF)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Karydakis flap (KF)
Number of subjects: 102
Study: 37351709

Group type: EXPERIMENTAL
Intervention: Substance use among male couples
Number of subjects: 934
Study: 37351781

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study: 37351798

Group type: EXPERIMENTAL
Intervention: Clinical pathway implementation
Number of subjects: 2878
Study: 37351885

Group type: EXPERIMENTAL
Intervention: REBECCA intervention (nurse navigation and symptom screening)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: REBECCA intervention
Number of subjects: 309

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 309
Study: 37351932

Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI) treatment delivered via telephone for smoking cessation.
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standard evidence-based behavioral treatment delivered via telephone.
Number of subjects: 1200
Study: 37351941

Group type: EXPERIMENTAL
Intervention: Pathway Platform (digital tool)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathway app (earlier iteration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathway Platform
Number of subjects: 0
Study: 37352120

Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Receipt of colloid
Number of subjects: 100
Study: 37352144

Group type: EXPERIMENTAL
Intervention: Symptomatic participants (76.2%)
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Symptom duration correlated with disease severity
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Lung disease
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Race
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Global region
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Prolonged viral shedding
Number of subjects: 759
Study: 37352211

Group type: EXPERIMENTAL
Intervention: Onset of PASC, measured by signs and symptoms.
Number of subjects: 14880

Group type: EXPERIMENTAL
Intervention: Quarterly questionnaires about symptoms, social determinants, vaccination status, and interim SARS-CoV-2 infections.
Number of subjects: 14880

Group type: EXPERIMENTAL
Intervention: Biospecimens and physical/laboratory examinations at approximately 0, 90, and 180 days from infection or negative test date.
Number of subjects: 14880

Group type: EXPERIMENTAL
Intervention: Logistic regression and proportional hazards regression analysis.
Number of subjects: 14880
Study: 37352262

Group type: EXPERIMENTAL
Intervention: Tacrolimus/methotrexate (full-MTX)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tacrolimus/reduced-dose methotrexate/mycophenolate (mini-MTX/MMF)
Number of subjects: 96
Study: 37352266

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg and brentuximab vedotin (BV) 1.8 mg/kg once every 3 weeks until disease progression or unacceptable toxicity.
Number of subjects: 29
Study: 37352284

Group type: COMPARATOR
Intervention: Structured Emotionally Focused Family Therapy (EFFT)
Number of subjects: 20
Study: 37352322

Group type: EXPERIMENTAL
Intervention: Nifurtimox 60-day treatment regimen
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Nifurtimox 30-day treatment regimen
Number of subjects: 127
Study: 37352479

Group type: EXPERIMENTAL
Intervention: Lasofoxifene combined with abemaciclib
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional model
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Just-in-TIME model
Number of subjects: 29
Study: 37352498

Group type: EXPERIMENTAL
Intervention: pomalidomide 5 mg orally for 21 days of 28-day cycles for up to 1 year
Number of subjects: 19
Study: 37352520

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 49
Study: 37352525

Group type: EXPERIMENTAL
Intervention: New procedure: left atrial geometric volume reduction combined with left appendage base closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cox-Maze IV treatment
Number of subjects: 0
Study: 37352612

Group type: EXPERIMENTAL
Intervention: BNZ-1
Number of subjects: 0
Study: 37352806

Group type: EXPERIMENTAL
Intervention: Digital phenotype profile (DPP) tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted support vector machine with leave-one-subject-out-cross-validation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning models (support vector machine and decision tree)
Number of subjects: 0
Study: 37352880

Group type: EXPERIMENTAL
Intervention: Aerosolised Ad5-nCoV
Number of subjects: 10267

Group type: COMPARATOR
Intervention: Inactivated vaccine
Number of subjects: 10267
Study: 37353155

Group type: EXPERIMENTAL
Intervention: Degree of iliac venous outflow obstruction (IVOO) categorized as obstruction <50% (category 1), 50% to 79% (category 2), and ≥80% (category 3)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Deep venous reflux (DVR)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Previous deep vein thrombosis (DVT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Left limb involvement
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Venous clinical severity score (VCSS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Reflux multisegment score (RMS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Linear association between the degree of IVOO and reflux
Number of subjects: 51
Study: 37353154

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Anticoagulation alone (ACA)
Number of subjects: 72
Study: 37353270

Group type: EXPERIMENTAL
Intervention: CAR T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 37353277

Group type: EXPERIMENTAL
Intervention: Continue disease-modifying therapy
Number of subjects: 259

Group type: COMPARATOR
Intervention: Discontinue disease-modifying therapy
Number of subjects: 259
Study: 37353278

Group type: EXPERIMENTAL
Intervention: Descartes-08 (autologous anti-BCMA rCAR-T therapy)
Number of subjects: 14
Study: 37353342

Group type: EXPERIMENTAL
Intervention: Enhanced diagnostic workup
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Cardiovascular MR imaging (CMR)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Study-related ECG monitoring
Number of subjects: 356

Group type: COMPARATOR
Intervention: Routine monitoring
Number of subjects: 356
Study: 37353450

Group type: EXPERIMENTAL
Intervention: HepB-CpG vaccine
Number of subjects: 10
Study: 37353495

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI) treatment
Number of subjects: 48
Study: 37353645

Group type: EXPERIMENTAL
Intervention: Supportive Parenting for Anxious Childhood Emotions (SPACE)
Number of subjects: 15
Study: 37353654

Group type: EXPERIMENTAL
Intervention: Endoscopic vacuum therapy (EVT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Self-expandable metal stent (SEMS)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment timing
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Total number of procedures per patient
Number of subjects: 44

Group type: COMPARATOR
Intervention: SEMS complications
Number of subjects: 44
Study: 37353726

Group type: EXPERIMENTAL
Intervention: Hunger measured on a 0-10 numeric rating scale
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Thirst measured on a 0-10 numeric rating scale
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Antral grades and numeric rating scale for thirst
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Antral grades and numeric rating scale for hunger
Number of subjects: 515
Study: 37353788

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor inhibitor (TNFi)
Number of subjects: 437
Study: 37353795

Group type: EXPERIMENTAL
Intervention: Remotely delivered TEACH program plus treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 0
Study: 37353798

Group type: EXPERIMENTAL
Intervention: Recognition-based non-financial incentives package (certificates and government-branded jackets awarded in a public ceremony)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Recognition-based non-financial incentives package
Number of subjects: 240
Study: 37353809

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 37353855

Group type: EXPERIMENTAL
Intervention: Cumulative physiological stress load
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cumulative physiological stress load components (DHEA-S, urinary norepinephrine)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cumulative physiological stress load components (waist circumference, blood pressure, CRP, HbA1c)
Number of subjects: 66
Study: 37354000

Group type: EXPERIMENTAL
Intervention: Telomere Shortest Length Assay (TeSLA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (n=22)
Number of subjects: 18
Study: 37354048

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir 300 mg/100 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ritonavir 100 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dabigatran 75 mg
Number of subjects: 36
Study: 37354069

Group type: EXPERIMENTAL
Intervention: Vorasidenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37354146

Group type: EXPERIMENTAL
Intervention: PADN
Number of subjects: 98

Group type: COMPARATOR
Intervention: sham + sildenafil
Number of subjects: 98
Study: 37354201

Group type: EXPERIMENTAL
Intervention: Social Intelligence Training (SIT)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Attention Control Condition (ACC)
Number of subjects: 349
Study: 37354245

Group type: EXPERIMENTAL
Intervention: Lifestyle change intervention for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 37354260

Group type: EXPERIMENTAL
Intervention: Optilume BPH Catheter System
Number of subjects: 80
Study: 37354276

Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (DMF)
Number of subjects: 5251
Study: 37354546

Group type: EXPERIMENTAL
Intervention: Bempedoic acid, 180 mg daily (n=2100)
Number of subjects: 13970

Group type: EXPERIMENTAL
Intervention: Bempedoic acid (n=2100)
Number of subjects: 13970

Group type: COMPARATOR
Intervention: Placebo (n=2106)
Number of subjects: 13970
Study: 37354554

Group type: EXPERIMENTAL
Intervention: 8 weeks of daily low-dose hCG (260 IU recombinant hCG) administration before IVF/ICSI cycle
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cycle (no hCG priming)
Number of subjects: 20
Study: 37354562

Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 588

Group type: COMPARATOR
Intervention: Once-daily insulin degludec
Number of subjects: 588
Study: 37354762

Group type: EXPERIMENTAL
Intervention: Ultraprocessed food (UPF) consumption
Number of subjects: 305
Study: 37354778

Group type: EXPERIMENTAL
Intervention: Platinum chromium everolimus-eluting stent implantation
Number of subjects: 4175
Study: 37354947

Group type: EXPERIMENTAL
Intervention: Family Bridge Program
Number of subjects: 60
Study: 37354976

Group type: EXPERIMENTAL
Intervention: Lactase persistence (LP) genotype individuals
Number of subjects: 279

Group type: COMPARATOR
Intervention: Lactase nonpersistent (LNP) individuals consuming more than 12.46 g/d
Number of subjects: 279

Group type: COMPARATOR
Intervention: LNP individuals consuming the upper tercile of lactose
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Elevated lactose consumption in individuals with the LNP genotype
Number of subjects: 279
Study: 37354978

Group type: EXPERIMENTAL
Intervention: Intensive arm
Number of subjects: 1678

Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 1678